arbekacin

Ligand id: 7345

Name: arbekacin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 16
Hydrogen bond donors 11
Rotatable bonds 11
Topological polar surface area 297.27
Molecular weight 552.31
XLogP -5.86
No. Lipinski's rules broken 3

Molecular properties generated using the CDK

Classification
Compound class Natural product or derivative
IUPAC Name
(2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide
International Nonproprietary Names
INN number INN
5914 arbekacin
Synonyms
arbekacin sulfate
NPC-14
Database Links
CAS Registry No. 51025-85-5 (source: Scifinder)
ChEBI CHEBI:37922
ChEMBL Ligand CHEMBL426926
DrugBank Ligand DB06696
PubChem CID 68682
Search Google for chemical match using the InChIKey MKKYBZZTJQGVCD-XTCKQBCOSA-N
Search Google for chemicals with the same backbone MKKYBZZTJQGVCD
Search PubMed clinical trials arbekacin
Search PubMed titles arbekacin
Search PubMed titles/abstracts arbekacin
Wikipedia Arbekacin
Comments
Several aminoglycoside antibiotics have been reported to have the ability to promote mRNA translation even in the presence of premature termination codons (PTCs) in mutated genes. In the absence of pharmaceutical intervention, the ribosomal translation process produces truncated, often non-functional protein products. However, in the presence of such compounds the ribosomes 'readthrough' the PTCs, producing increased amounts of full-length, functional protein. This developing pharmaceutical intervention has been termed 'readthrough strategy'.